Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
4(50.0%)
Phase 1
4(50.0%)
8Total
Phase 2(4)
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06340711Phase 2Recruiting

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Role: collaborator

NCT03921021Phase 2Completed

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Role: collaborator

NCT04685499Phase 2Terminated

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Role: collaborator

NCT03172819Phase 1Completed

Special Combination of OBP-301 and Pembrolizumab

Role: collaborator

NCT03190824Phase 2Unknown

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Role: collaborator

NCT02414516Phase 1Unknown

A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Role: lead

NCT03213054Phase 1Unknown

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Role: lead

NCT02293850Phase 1Unknown

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Role: lead

All 8 trials loaded